Cancer patients' experiences with immune checkpoint modulators: A qualitative study.
Adult
Aged
Aged, 80 and over
Drug-Related Side Effects and Adverse Reactions
/ diagnosis
Female
Follow-Up Studies
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Male
Middle Aged
Neoplasms
/ drug therapy
Patient Reported Outcome Measures
Prognosis
Qualitative Research
Quality of Life
Severity of Illness Index
Young Adult
Health-related quality of life
costimulatory antibodies
immune checkpoint inhibitors
immunotherapy
patient experiences
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
06
08
2019
revised:
24
01
2020
accepted:
25
01
2020
pubmed:
3
3
2020
medline:
15
5
2021
entrez:
3
3
2020
Statut:
ppublish
Résumé
Minimal qualitative data exist on the experiences of cancer patients treated with immune checkpoint inhibitors or costimulatory antibodies. Understanding the day to day experiences of patients being treated with immune checkpoint modulators, and how these relate to their health-related quality of life, can inform future research and lead to better clinical decision-making and care. We report here the first in depth qualitative study to consider patients' diverse and complex experiences with immune checkpoint modulators, with a focus on side effects and how these impact daily life. This single-center qualitative study was based on focus groups and semistructured interviews. Patients who were being treated or who had been treated with immune checkpoint modulators within the last year for a range of cancer diagnoses were recruited. Interpretive description informed our inductive, iterative approach to analysis. Eight themes were identified, characterizing the complexity of these patients' lived experiences: major categories of side effects experienced and how they impacted patient well-being; the heterogeneous nature of side effects experienced; living with uncertainty; reframing the meaning and severity of SEs; focus on survival, hope, and being positive; acceptance and adaptation; feeling supported; and faith in medical innovation. Throughout their accounts, participants highlighted the profound impact that immune checkpoint modulators had on their daily lives. This is the first in-depth qualitative study into patient accounts of their experiences of treatment with immune checkpoint modulators, related side effects, and how it impacted their daily lives. This research is an integral initial step in developing an instrument that will assess treatment-related side effects in patients treated with this form of therapy.
Sections du résumé
BACKGROUND
Minimal qualitative data exist on the experiences of cancer patients treated with immune checkpoint inhibitors or costimulatory antibodies. Understanding the day to day experiences of patients being treated with immune checkpoint modulators, and how these relate to their health-related quality of life, can inform future research and lead to better clinical decision-making and care. We report here the first in depth qualitative study to consider patients' diverse and complex experiences with immune checkpoint modulators, with a focus on side effects and how these impact daily life.
METHODS
This single-center qualitative study was based on focus groups and semistructured interviews. Patients who were being treated or who had been treated with immune checkpoint modulators within the last year for a range of cancer diagnoses were recruited. Interpretive description informed our inductive, iterative approach to analysis.
RESULTS
Eight themes were identified, characterizing the complexity of these patients' lived experiences: major categories of side effects experienced and how they impacted patient well-being; the heterogeneous nature of side effects experienced; living with uncertainty; reframing the meaning and severity of SEs; focus on survival, hope, and being positive; acceptance and adaptation; feeling supported; and faith in medical innovation. Throughout their accounts, participants highlighted the profound impact that immune checkpoint modulators had on their daily lives.
CONCLUSION
This is the first in-depth qualitative study into patient accounts of their experiences of treatment with immune checkpoint modulators, related side effects, and how it impacted their daily lives. This research is an integral initial step in developing an instrument that will assess treatment-related side effects in patients treated with this form of therapy.
Identifiants
pubmed: 32119767
doi: 10.1002/cam4.2940
pmc: PMC7196048
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3015-3022Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
BMJ Open. 2014 Jun 12;4(6):e005285
pubmed: 24928595
Health Serv Res. 1999 Dec;34(5 Pt 2):1189-208
pubmed: 10591279
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Eur J Cancer Care (Engl). 2016 Nov;25(6):1056-1064
pubmed: 26094639
Chronic Illn. 2017 Jun;13(2):88-99
pubmed: 27539955
Res Nurs Health. 2008 Aug;31(4):391-8
pubmed: 18203128
Soc Sci Med. 2008 Jul;67(1):79-87
pubmed: 18450347
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Psychol Health. 2014;29(2):141-61
pubmed: 24070024
Ann Oncol. 2017 Oct 1;28(10):2377-2385
pubmed: 28945858
Cancer Med. 2020 May;9(9):3015-3022
pubmed: 32119767
Health (London). 2006 Jul;10(3):323-44
pubmed: 16775018
Psychooncology. 2004 Oct;13(10):729-39
pubmed: 15386642
Eur J Cancer Care (Engl). 2016 Jan;25(1):79-92
pubmed: 25752741
Cancer Treat Rev. 2016 Mar;44:51-60
pubmed: 26874776
Ann Oncol. 2016 Apr;27(4):559-74
pubmed: 26715621
Cancer. 2020 Apr 1;126(7):1550-1558
pubmed: 31914209
Eur J Cancer Care (Engl). 2018 Jan;27(1):
pubmed: 28892215
J Clin Oncol. 1993 Mar;11(3):570-9
pubmed: 8445433
Int Immunopharmacol. 2018 Sep;62:29-39
pubmed: 29990692
BioDrugs. 2016 Dec;30(6):571-584
pubmed: 27848165
Res Nurs Health. 1997 Apr;20(2):169-77
pubmed: 9100747
Sociol Health Illn. 2017 Mar;39(3):458-473
pubmed: 27577849
Qual Life Res. 2007 Dec;16(10):1627-34
pubmed: 17917793